Ceftriaxone
| Evidence Level: L5 | Predicted Indications: 5 |
Table of Contents
Ceftriaxone: Polyclonal hyperviscosity syndrome
One-Sentence Summary
Ceftriaxone is a third-generation cephalosporin antibiotic that works by blocking bacterial cell wall synthesis. The TxGNN model predicts it may be effective for polyclonal hyperviscosity syndrome, with a score of 0.9939. There are currently no clinical trials and no publications supporting this prediction, so it rests on model output alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Polyclonal hyperviscosity syndrome |
| TxGNN Prediction Score | 0.9939 |
| Evidence Level | L5 |
| India Market Status | Listed in a compiled Indian medicine price dataset (at least 20) – CDSCO approval status is not included in this data |
| Number of Listed Products | at least 20 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Ceftriaxone is a third-generation cephalosporin that inhibits bacterial cell wall synthesis. Detailed mechanism of action data is not available in the data compiled for this report.
Polyclonal hyperviscosity syndrome is a haematological and immunological condition driven by elevated immunoglobulin levels. An antibacterial agent would not be expected to act on this process, and no mechanistic link has been identified.
The high TxGNN score is a model prediction only. No trial or publication tests ceftriaxone in this disease, so the prediction should be treated as a hypothesis with no supporting evidence.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
India Market Information
Ceftriaxone is marketed in India. At least 20 valid single-ingredient licences are recorded, and the list may be partial. No approved indication text is recorded in the local data.
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| Registration No. 54887 | Cefset-TX 1000mg/125mg Injection | Powder for injection (vial) | Not available |
| Registration No. 117657 | Keftragard 250mg/125mg Injection | Injection (vial, 5 ml) | Not available |
| Registration No. 146757 | Micef TZ 1000mg/125mg Injection | Injection (vial) | Not available |
| Registration No. 245340 | Xonejet 500mg Injection | Injection (vial) | Not available |
| Registration No. 57118 | Colticef 250mg Injection | Injection (vial) | Not available |
Safety Considerations
- Drug Interactions: 164 interactions were found in the data compiled for this report. The main major-level interactions are with calcium chloride, calcium glucoheptonate and calcium gluconate. Moderate-level interactions include kanamycin, neomycin, streptomycin and picosulfuric acid.
Please refer to the package insert for other safety information, including warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has no clinical trials or publications behind it, and no plausible mechanism links an antibacterial to a disease of raised immunoglobulins. The evidence level is L5.
To proceed, the following is needed:
- Evidence that ceftriaxone acts on the pathophysiology of polyclonal hyperviscosity syndrome, such as preclinical or mechanistic studies
- Detailed mechanism of action data
- Package insert warnings and contraindications for the marketed products
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.